Skip to content
Epclusa-velpanat

Gilead Science, INC

Epclusa-velpanat


"Epclusa" contains the Drugs / Molecules called “Velpatasvir & Sofosbuvir”. Epclusa has high overall cure rates of 99% for GT2 patients and 95% for GT3 patients. Velpanat was also found to be highly effective in patients with GT1, GT4, GT5 and GT6, with overall cure rates ranging from 97–100%.

“Velpanat” is the generic version of "Epclusa" and both contains same drugs “Velpatasvir & Sofosbuvir”.


Indication

Epclusa is helpful for treatment of all Hepatitis C adults that are suffering from genotype 1-6 chronic hepatitis C virus.

Note

SIDE EFFECTS :

  • Common side effects include muscle pains, headache, nausea, rash, diarrhea, insomnia and cough.
  • More severe reactions are connected with allergic reactions to the medications and cardiovascular problems.

INTERACTIONS :

  • For the HIV combination Efavirenz / Emtricitabine / Tenofovir, which reduces the area under the curve (AUC) of Velpatasvir by about 50%, and the CYP3A4 and Pgp inducer Rifampicin, which reduces its AUC by about 80%, rendering it likely ineffective.
  • Digoxin is eliminated by Pgp; its AUC is increased by about 30% in combination with Velpatasvir and Sofosbuvir.
  • Substances that reduce gastric acid, such as Antacids, H2 blockers, and Proton pump inhibitors, reduce Velpatasvir AUC by 20–40%

OVERDOSE :

  • Do not use more than prescribed dose.
  • If you suspect you may have overdosed, call your healthcare provider.
  • Do not take extra dose to make up for the missed dose.

 

Precaution

  • Epclusa is a prescription drug and should be used under proper medical guidance and advice.
  • Caution should be exercised in patients with history of stomach problem, liver, kidney, or heart disease during pregnancy and breastfeeding.

 

Updated On Oct 26, 2019 by Admin

Strength

100 mg Velpatasvir / 400 mg Sofosbuvir

Packing

1 X 28 Tablets (Plastic Container)

Storage

Store at room temperature

Epclusa-velpanat also available as


Fast moving

NATCO PHARMA LIMITED (INDIA)

Velpanat


“Velpanat” contains the Drugs / Molecules called “Sofosbuvir & Velpatasvir”.

Velpanat has high overall cure rates of 99% for GT2 patients† and 95% for GT3 patients. Velpanat was also found to be highly effective in patients with GT1, GT4, GT5 and GT6, with overall cure rates ranging from 97–100%.





Related Products


NATCO PHARMA LIMITED (INDIA)

Velpanat

NATCO PHARMA LIMITED (INDIA)

Sofosbuvir & velpatasvir-velpanat

Hetero Healthcare Ltd. (INDIA)

Ledifos

Mylan

Mydacla


Most Viewed Products


CIPLA LTD. (INDIA)

Abiraterone acetate-xbira

NATCO PHARMA LIMITED (INDIA)

Bendamustine-bendit

CIPLA LTD. (INDIA)

Bicalutamide-cassotide

NATCO PHARMA LIMITED (INDIA)

Bortezomib-bortenat

NATCO PHARMA LIMITED (INDIA)

Erlonat

Biocon Limited

Everolimus-evertor

NATCO PHARMA LIMITED (INDIA)

Exemestane-xtane

NATCO PHARMA LIMITED (INDIA)

Geftinat

NATCO PHARMA LIMITED (INDIA)

Glatiramer acetate-glatimer

NATCO PHARMA LIMITED (INDIA)

Ledipasvir & sofosbuvir-hepcinat lp

NATCO PHARMA LIMITED (INDIA)

Lenalidomide-lenalid

NATCO PHARMA LIMITED (INDIA)

Pomalidomide-pomalid

NATCO PHARMA LIMITED (INDIA)

Sofosbuvir & velpatasvir-velpanat

NATCO PHARMA LIMITED (INDIA)

Sorafenib-sorafenat

CIPLA LTD. (INDIA)

Tenofovir-tenvir

Quick Query

Direct to your Phone